Roughly 1 in 50 promising cancer drug candidates makes it to market. What’s holding the other 49 back?
A new analysis of public data shows some hospitals are penalized for patients’ readmissions, though they do better at keeping patients alive.
Even when clinicians agree an MRI or CT isn’t needed, referral and patient factors get in the way, a new survey shows.
A new study finds doctors are appropriately using a genetic test to measure breast cancer recurrence risk and to make tailored treatment recommendations.
Part of the national Cancer Moonshot, a new data repository of cancer patients’ analyzed blood samples aims to stimulate translational research across industry and academia.
Cutting-edge patient-centered “smart tests” will allow clinicians to evaluate specific quality of life concerns for individuals with Huntington’s disease.